Banque Pictet & Cie Sa Neurocrine Biosciences Inc Transaction History

Banque Pictet & Cie Sa

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$94.11 - $123.02 $365,429 - $477,686	-3,883 Reduced 31.2%	8,564 $866,000
Q4 2022 Feb 06, 2023	SELL	$106.72 - $127.06 $379,389 - $451,698	-3,555 Reduced 22.22%	12,447 $0
Q3 2022 Nov 10, 2022	BUY	$92.03 - $107.81 $66,261 - $77,623	720 Added 4.71%	16,002 $1.7 Billion
Q2 2022 Aug 08, 2022	SELL	$75.79 - $100.07 $120,960 - $159,711	-1,596 Reduced 9.46%	15,282 $1.49 Million
Q1 2022 May 04, 2022	BUY	$72.45 - $94.81 $1.22 Million - $1.6 Million	16,878 New	16,878 $1.58 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.